Pump technology sustains insulin patch

By Susan Gotensparre

- Last updated on GMT

Related tags: Liquid

US-based start-up company Medipacs is developing a miniaturised
digital pump, no bigger than a quarter, which could become the
first patch-like product to help diabetics manage their insulin

Medipacs has been in talks with companies to produce a patch able to hold a 72-hour insulin dose, whilst pumping out one millilitre over 24 hours, which will match the shelf life of insulin.

The patch is a scaled down version of a larger pump, also in development, which would be used for delivering active drugs over a two-week period. Another feature is that the patch is flexible enough to be programmed with a patient's required delivery rate.

The firm expects the patch to hit the $2bn drug delivery patch market in 24 to 30 months.

Medipacs' patch is attached to the skin by adhesive and is used with skin barrier technologies, such as micro needles, phonophoresis (ultrasound) and electrophoresis (applied electric field).

The firm explains that the pump runs on a small amount of power, less than three volts. The system's backpressure is more than enough to deliver insulin, which would require five pounds per square inch (psi) but can operate at a higher psi so it can be used for liquid pharmaceuticals with a higher viscosity.

The pump is still in research and development but the technology has been proven to operate over 72 hours and can sustain backpressure of 30 psi. The company hopes that larger pump will become a commercial reality within 18 to 24 months, where it would enter an infusion pump market worth $2bn (€1.54bn).

"Ultimately we want the pump to be able to run continuously for extended lengths of time as long as two weeks to a month so it can be used in the larger form of a portable infusion pump. The Medipacs technology will have a dramatic impact on lowering the cost of healthcare for patients that need delivery of liquid drugs and fluids over extended times,"​ said Sonia Vohnout, Medipacs systems engineer.

" We have proven the concept and are now working on medical applications for the first commercialized products, once we have funding to proceed we are 18-24 months from market introduction,"​ said Mark Banister, president of Medipacs, told In- PharmaTechnologist.com.

Related topics: Ingredients, Delivery technologies

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more